The document details precise dosing regimens for YERVOY (ipilimumab) across multiple indications, emphasizing weight-based and combination protocols.
YERVOY is administered intravenously, with dosage and frequency tailored to the specific malignancy and patient characteristics. For unresectable or metastatic melanoma, the recommended dose is 3 mg/kg every 3 weeks for up to 4 doses, either as monotherapy or in combination with nivolumab.
In renal cell carcinoma and certain colorectal cancers, combination regimens with nivolumab are specified, with YERVOY dosed at 1 mg/kg or 3 mg/kg depending on the indication. Pediatric dosing is weight-adjusted. Administration requires dilution and infusion over 30 minutes, with strict adherence to preparation and administration protocols.

